Fig. 5: V-aCD3 impedes growth of cancer cells in vivo in an orthotopic mouse bladder cancer model.

A Tumor size (bioluminescence signal in bladder from cancer cells). Mice were transfused with human PBMC on days 0 and 5 after tumor injection and received treatment with V-aCD3 (solid black line), aCD3-scFc (green line), rVAR2 (dashed black line), or PBS (red line). Tumor growth was statistically significantly impeded in mice treated with V-aCD3 compared to mice treated with PBS, rVAR2, or aCD3-scFc (P < 0.006, generalized least square model for log transformed panel data). B Tumor size of individual mice in the four groups, error bars are SEM of 8–9 mice. C Tumor size (mm3) measured by ultrasound on day 25. The tumor size of mice treated with V-aCD3 were statistically significantly lower than in mice treated with PBS or aCD3-scFc (P = 0.028 and P = 0.006, respectively, Wilcoxon test). D Bladder weight including the tumor volume measured when mice were sacrificed on day 25. The bladder weight of mice treated with V-aCD3 were statistically significantly lower than in mice treated with PBS or aCD3-scFc (P = 0.035 and P = 0.048, respectively, Wilcoxon test).